valu usd unless otherwis note
medic devic consum busi
view manag made convinc argument
strategi portfolio address challeng medic devic
consum segment howev given slow growth highli
competit natur market challeng exist execut
key turnaround expect maintain leadership higher
growth market vision electrophysiolog devic
beauti consum
set goal grow faster market medic devic
end-market annual growth rate around
certain end-market vision electrophysiolog
advanc surgeri grow line market compens
slower-growth orthoped categori new product launch
year qualiti improv adapt
busi model chang environ element
strategi achiev goal
orthoped manag outlin step revers trend
spine knee given slow market competit market
leader compani gain share sever
quarter spine pose biggest challeng turnaround strategi
spine target four high-growth segment minim invas surgeri
deform complex cervic age spine knee manag
believ attun primari attun revis system attun
cementless expect approv deliv better result
vision clear strategi extend leadership contact lens
forecast segment within vision contact lens
surgic grow compound-annual-growth-rate plan launch
new product year contact lens among
first transit contact lens expect launch next year
integr abbott medic optic span countri
complet disrupt custom
relaunch babi oral brand exemplifi strategi
refresh consum sluggish growth consum last year
caus deceler end-market growth inventori
destock jnj commerci model evolv compet rapidli
chang market consum packag good relaunch babi
johnson brand plan later year listerin
import case studi new go-to-market strategi johnson
babi listerin icon consum brand
turnaround strategi work jnj growth remain stabl
segment grow market
segment face slower growth next year owe gener competit
therefor devic consum step consolid
organ growth continu current pace also
essenti jnj multipl recov
dissemin may produc may price prior trade day market close estimate unless otherwis note
capit market appreci consider institut investor all-america research survey
forecast organ revenu growth
oper growth bp higher organ revenu
growth higher last year account
prior period adjust despit greater remicad sale
eros tougher year-over-year comp
expect organ growth mid-single-digit rang
pharmaceut segment princip driver jnj revenu
earn growth valuat share
mega-blockbust
contribut new product main growth driver
segment mega-blockbust brand
ww annual peak sale potenti billion
stelara imbruvica darzalex xarelto invega
sustenna/trinza ww sale five brand
estim
ww sale mega-blockbust increas led
stelara imbruvica darzalex new brand tremfya
erleada contribut million
pharmaceut pipelin enough late-stag compound
produc steadi flow new drug nme
esketamin erdafitinib expect submit
approv year could market
manag share target nme file
least billion peak annual sale
esketamin studi treatment-resist
depress major depress disord patient
risk suicid ideat erdafitinib expand jnj oncolog
portfolio solid tumor
franchis well manag laid four-
prong growth strategi two key brand opsumit
uptravi frequent earlier use combin
regimen pah treatment improv patient respons
extend treatment durat expand usag new
patient segment broaden geograph reach
brand
bloomberg capit market estim upside/downside/target
arriv price target use sum-of-the-
part sotp price-to-earnings analysi valu three segment
medic devic consum separ
base peer group multipl base case estim
assum mid-single-digit oper growth includ
low-single-digit organ growth exclud
margin expans share buyback price
target impli price-to-earnings multipl ep estim
 lift revenu growth basi point
restructur portfolio ration lead superior
leverag rel base case scenario
pharmaceut price rhetor lead legisl
chang govern negoti price
multipl ep estim y/i
assumpt
aggress eros remicad brand
biosimilar gener competit lack depress
revenu growth neg leverag dent
multipl downsid scenario impli
price-to-earnings multipl y/i ep estim
assumpt
context year event growth lag goal set two year ago
attend jnj biennial busi review medic devic consum segment
yesterday segment attract attent within jnj
portfolio two segment make import contribut consolid revenu
pre-tax margin follow figur year illustr
medic devic ww revenu billion jnj revenu
report growth exclud fx
organ growth
pre-tax margin non-gaap
consum billion jnj revenu
organ growth
pre-tax margin non-gaap
report growth exclud fx
yesterday investor event held crucial time compani revenu growth
pressur segment adjust currenc acquisit divest
medic devic revenu growth five straight quarter
consum growth cross threshold past quarter exhibit
growth trend fallen short goal share investor event
summar next section
exhibit year-over-year growth past quarter medic devic consum segment
goal share busi review
goal medic devic segment includ
medic devic grow revenu faster end-market weight averag
growth end-market accord manag
achiev annual cost save rang million billion
major regulatori file
increas new product fresh index
fresh index percentag sale aris product launch previou
multi-product contract orthoped surgeri custom account
revenu franchis
-y/i growth adjust divest -y/i growth adjust divest -y/i growth adjust divest -y/i growth adjust divest fx medic suppli devic
goal consum segment includ
revenu growth market growth
increas earn faster pace revenu reach benchmark profit
mega-brand account consum revenu
brand johnson babi neutrogena listerin
billion aveeno zyrtec clean benadryl carefre le petit marseillai
band-aid tylenol motrin
sixti percent plan revenu growth come emerg market
orthoped hamper medic devic growth
medic devic revenu growth fell well short manag goal
mention major reason weak orthoped surgeri
two-third jnj ww medic devic revenu orthoped account
medic devic revenu surgeri anoth intern revenu contribut
two product franchis respect investor day
manag place knee trauma among prioriti platform within
orthoped hip constitut core platform spine fell within base busi
within surgeri endocutt robot classifi prioriti platform
biosurgeri consid core platform among prioriti platform trauma
endocutt done well knee much
next exhibit show growth rate individu categori within segment
geographi recent quarter spine world-wide singl biggest
drag within orthoped past two year knee also come signific
pressur spine manag cite product delay one reason market share
loss mostli smaller competitor end-market soft help either
manag attribut reimburs challeng sale forc attrit
compound problem knee count on-going launch attun
revis system recent doctor day reveal less favor view attun
intern knee sale also affect introduct price cap india
exhibit year-over-year growth past quarter orthoped surgeri
rel orthoped surgeri done better perform help tuck-in
acquisit advanc surgeri stood endocutt biosurgeri
contribut specialti surgeri under-perform regularli might suitabl
candid divestitur opinion
growthintern growth excl medic suppli devic
vision amass scale make real differ
vision account ww medic devic revenu made three
acquisit last year significantli increas size breadth vision
portfolio largest three februari acquisit abbott medic
optic turn smart strateg move alway strong
contact lens acuvu brand market grow mid- high-singl
digit world-wide gain possess portfolio intraocular lens implant
cataract surgeri amo acquisit surgic busi also grow
compar rate legaci vision busi vision face type
price pressur util trend franchis within medic devic face
electrophysiolog bright spot small rel size
revenu growth electrophysiolog exceed consist basi past
sever year ep count one prioriti platform estim ww ep
market grow compound-annual-growth-rate investor day
forecast prove conserv thu far jnj newer product offer ablat
advanc cathet enabl modest share gain accord manag
consum beauti over-the-counter done well oral babi
four product categori depict next exhibit account ww consum
revenu over-the-counter beauti compris consum revenu product
categori achiev market revenu growth declin over-the-counter
busi due stock channel prior year quarter similarli
over-the-counter sale growth neg impact due inventori build
launch rapid releas chewabl formul children tylenol
howev babi oral gone sever quarter sale declin
especi weigh overal consum segment revenu growth
babi come pressur intern well indic consum
prefer market dynam shift across world oral need
new market strategi well
exhibit year-over-year growth past quarter select product franchis within consum
look ahead takeaway busi review
medic devic orthoped expect better vision
ep remain key growth driver
medic devic consum busi review manag convey
follow goal medic devic segment
return market growth end-market annual growth rate
around accord manag end-market growth rate within
sequenti improv revenu growth balanc organ growth
 revenu flat y/i revenu increas
major new product launch later
new product develop intern contribut billion annual sale
investor event goal billion new product sale
suppli chain optim continu even though cost save target
million billion achiev
verb surgic robot system expect launch sever market
system advanc sinc investor event manag consid
truli differenti commerci avail system other
exhibit jnj strategi return medic devic segment market growth next two year
expect executionimprovingqualitysimplifyingoperationsinnovatingbusinessmodelsuniquelyleveragingsci technolog scale expertiseprovidingvaluebeyondtheproductor traditionalpointofcarereimaginingprofession educationrobust holist innovationand portfolioshapingstrategyacceleratedd pacedoubl newproduct managementstrengtheningourfoundationtoimprov flexibl improvinggpandcustom responsivenessevolvinggo-to-marketmodelsandchannelsinrespons tocustomerne managedservic careadvantag asc myacuvu comincreasinginvestmentinsalesforcecoverag train andcompensationactivelyco-creatingwithhealthsystemsto improveoutcom increasepatientsatisfact andreducecostsintroducingdigitally-enabledservicesandtool tooptimizesurgeriesandorefficiencywith standardizedprocedur strengthensurgeon skillstohelppatientsbetterprepareforsurgeri andrecoveryregainingleadershipinprofessionaleduc withthegloballaunchofthejohnson johnson instituteanddifferentiatingtechnologywith theworld c-satsacquisit medic suppli devic
orthoped strateg prioriti spine knee similar
share execut key achiev better result
spine knee two challeng market jnj perspect right
compani experienc slower sale growth segment within orthoped
lost market share case exhibit therefor across board improv
orthoped necessari achiev jnj goal grow faster end-market
exhibit jnj sale growth compound-annual-growth-rate estim variou orthoped end-market
spine lower growth forecast ww market
compani lie second term market share global market leader
china emea sinc disrupt new product flow sale forc attrit
respons sale declin spine last year manag address
turnaround strategi target four high-growth segment spine minim invas surgeri
deform complex cervic age spine manag highlight focu area
event therefor besid launch new product superior execut
essenti revers trend manag also note stabil sale forc turnov
exhibit spine retain market share posit despit weak revenu growth
ww sale growth share cagrww market size initiativesstrengthenourcoreclos key portfoliogapsand updatekey spineplatformswithconcordelift symphonyoctplatformcontinuedsimplificationofcurrentportfolioimprovedfocusoncommercialexecut investmentinprofessionaleducationandenhancedaccesstoinstrumentsetsless invas surgeryreduceth impact ofsurgeryon patientsimproveclinicaland costoutcomesnormalizesurgeonvariationmov tooutpatientaddresstheagingspinebetterdiagnosticsslow/halt /reversedddspin mi internalestim market medic suppli devic
knee slip market share posit compani chang
ww market growth forecast remain make knee third biggest market
behind spine trauma within orthoped outlook jnj knee busi tie
success attun system perform attun primari knee
come question relat issu tibial loosen manag character
industry-wid problem main reason need revis knee surgeri
two year initi implant data four registri uk australia new zealand
michigan show attun perform consist total knee arthroplasti
class plan introduc attun cementless earli cementless highest
growth sub-seg knee market
exhibit knee howev slip count attun portfolio revers declin
stronger posit hip trauma market segment hip revenu
growth market past year full suit offer
implant autom digit solut instrument enabl among implant
acti total hip system design optim anterior approach techniqu
gain traction surgeon earlier week depuy synth agre acquir medic
enterpris distribut strengthen portfolio autom tool surgic
impactor alreadi use hip surgeri plan develop type
trauma maintain market leadership posit among major orthoped
market segment trauma second highest growth forecast sport medicin
launch cement augment nail system tfna first kind led
double-digit sale growth portfolio femor neck system femor
recon nail system expect introduc expand hip femur fractur
repair portfolio anoth notabl product maxfram fall digit
solut surgeri portfolio maxfram gradual correct bone soft tissu deform
upper lower extrem patient limb deform
kneesstrategicinitiativescontinueglobalexpansionofattuneprimarykneesystemwithavailabilityofattunefiveyearevidencedataand investmentin tuneincampaignattuneplatformgrowthdrivenfromglobalmarketavailabilityofnpi fb rp attunerevis stemmabletibiaandcementlessrptransformkneeproceduresforoutcomesandcost serveviaintuitionsoloattunekne revisionsystemsintuitionsoloinstrumentsattunecementlessfor market exhibit hip strateg prioriti revolv around acti impactor enabl technolog
exhibit trauma remain market leader bring innov solut market
hipsstrategicinitiativesdrivegrowthin corailandpinnaclebrandsworldwidevia meimpactorglobalexpansionoftheactistotalhipsystemdeliverenablingtechnologiesto improveoutcom andreducecostsexpandpresenceindualmobilitymarketactishipstemjoint pointm market coreplatformswithtfn-advancedproximalfemoralnailandintroductionof anatomicvalockinghandsystemexpandingourcompetitiveandmorecompleteportfoliointheelectivefootmarketwithexpandedindicationsforcontinuouscompressionimpl bmeacquisit transformkneeproceduresforoutcomesandcost serveviadistalradiussterilekitsvariableangl va lockinghandsystemtfn-advancedaugmentationdist radiu market medic suppli devic
vision portfolio breadth innov sustain
market growth categori contact lens surgic
forecast market segment within vision contact lens acuvu brand
surgic vision intraocular lens refract surgeri grow compound-annual-growth-rate
market share leader contact lens surgic vision
total ww sale alon two segment estim exceed billion
abbott medic optic fulli integr complex integr
process spread across countri took month achiev disrupt
custom surgic vision grew pro-forma basi
market leader intraocular lens uk germani canada korea
besid abbott medic optic acquisit bought two smaller compani
one compani start-up call tearscienc receiv fda approv first
treatment meibomian gland dysfunct mgd lead caus dri eye
treatment becom major product sinc dri eye patient mgd
million peopl world-wide suffer dri eye
plan launch new product year contact lens among
first transit contact lens chang color depend upon light intens
acuvu oasi transit first drug combin contact lens drug-elut
len help patient suffer ocular allergi launch oasi transit
exhibit vision pipelin maintain pace launch new product consist basi
pipelinewilladdressnewneedstateswith lens adapt toth light busi lifedrugcombin contactlens designedtob acombinationproductforrelief ofey allergyitchxlen worldsfirstsmart contact len targetingdynamicsolutionforpresbyopiatechnologydevelopmentformyopiacontrol dri eye symptom custom medic suppli devic
electrophysiolog neurovascular major growth
driver led strong end market new product
billion sale market share electrophysiolog biosens
webster busi forecast compound-annual-growth-rate result ww
market well billion atrial fibril af stroke princip end-
market compet within ep af major risk factor stroke af portfolio
includ high densiti map cathet paroxysm af intermitt af contact
forc sens deliv better lesion treatment rf balloon cathet multi-electrod
ablat due advanc techniqu total procedur time come
one-third around hour
plan expand beyond paroxysm af persist af recent finish
enrol precept studi clinicaltri gov identifi studi
object demonstr safeti effect thermocool smarttouch
sf cathet treat drug refractori persist af also introduc left atrial
appendag closur devic call wavecrest emea region wavecrest came
acquisit coherex
neurovascular increas invest tackl ischem stroke account
case stroke compani commerci embotrap emea expect
launch devic next month embotrap design trap blood clot
lead stroke embotrap came acquisit neuravi
exhibit strateg prioriti electrophysiolog
surgic robot still two year away
expect launch verb surgic robot major geograph market
line expect
believ robot surgeri earli stage adopt view robot surgeri
bridg laparoscopi digit surgeri estim complex
procedur still done open robot act enabl mi surgeri
compani share lot new detail regard verb surgic system howev
said system would differenti launch integr jnj digit ecosystem
would focu improv follow factor access reach footprint cost
lower cost system smaller footprint patient access workflow advanc
instrument visual data analytics/ connect prior research
indic verb surgic robot could four arm mount bed
featur surgeon consol surgeon sit upright verb surgic built
multipl work prototyp system complet procedur develop pre-
clinic set pre-submiss meet regulatori agenc scale
capabl commerci servic suppli chain educ manag said
system multiport multipl quadrant capabl broad rang
procedur perform system
also discuss co-develop partnership auri health
integr system robot control
agreement call co-develop
navig applic microwav ablat deliv via bronchoscop recal auri
health monarch platform first fda-clear robot platform diagnost
therapeut bronchoscop procedur auri health headstart expect file
fda approv flexibl cathet system year-end believ co-
develop partnership import one auri health give compani access
jnj neuwav ablat technolog jnj neuwav flex microwav ablat system
fda-clear flexibl microwav ablat probe co-develop agreement
further auri health long-term goal creat system abl detect treat
suspici nodul lung singl procedur
consum new strategi unveil return babi
oral path sustain growth
sluggish sale growth caus two factor manag said
deceler end-market growth inventori destock howev recent acquisit
vogu intern largest perform expect jnj commerci
model evolv compet rapidli chang market consum packag good
manag cite vogu shine exampl compet today
marketplac relaunch babi listerin two exampl new
strategi take advantag power global brand combin local
knowhow maxim brand valu
manag promis last quarter relaunch babi
portfolio occur unveil strategi investor day
global relaunch occur later year main element new product
develop commerci strategi design appeal millenni mom includ
new ingredi natur sustain new product packag
highlight uniqu benefit variou brand within johnson famili get
endors dermatologist pediatrician
simplifi product portfolio turn acceler product develop scale
bring innov johnson cottontouch cleanser lotion market
aggress pursu digit first commerci strategi take advantag jnj on-line
ecosystem babycent exist countri account consum
rapidli develop product meet local need exampl petit planet sold
first china e-commerce channel
manag use listerin exampl new commerci strategi oral
listerin one three consum brand annual ww sale billion
johnson babi neutrogena two listerin household brand
extens studi clinic studi manag believ attract new
user increas frequenc usag number swish significantli increas
market potenti listerin initi add million new
household new listerin custom complet brand refresh listerin
underway includ new packag graphic clearli highlight uniqu benefit
claim tier come three well new better price strategi
commerci roll-out new promot campaign happen countri
price target base sum-of-the-part sotp analysi target price-to-earnings
multipl base year medic devic consum segment
respect correspond peer group multipl
assign premium multipl segment
superior growth outlook compar peer pharmaceut segment contribut toward
price target medic devic consum price target impli blend
price-to-earnings multipl ep estim y/i basi
outperform rate share
risk rate price target
face risk typic global diversifi healthcar compani includ
slump navig fda may impedi price target rate
johnson johnson one largest diversifi healthcar busi
world oper compani encompass broad rang product across
healthcar field compani world-wide busi divid three main segment
medic devic diagnost sale consum
